Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Abstract CD19‐directed immunotherapy has become a cornerstone in the therapy of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). CD19‐directed cellular and antibody‐based therapeutics have entered therapy of primary and relapsed disease and contributed to improved outcomes in relapsed diseas...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Denis M. Schewe, Fotini Vogiatzi, Ira A. Münnich, Tobias Zeller, Roland Windisch, Christian Wichmann, Kristina Müller, Hilal Bhat, Elisa Felix, Dimitrios Mougiakakos, Heiko Bruns, Lennart Lenk, Thomas Valerius, Andreas Humpe, Matthias Peipp, Christian Kellner
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-02-01
Rangatū:	HemaSphere
Urunga tuihono:	https://doi.org/10.1002/hem3.48
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!